Background. The identification of pathway(s) playing a pivotal role in peritransplant detrimental inflammatory events represents the crucial step toward a better management and outcome of pancreatic islet transplanted patients. Recently, we selected the CXCR1/2 inhibition as a relevant strategy in enhancing pancreatic islet survival after transplantation. Methods. Here, the most clinically used anti-inflammatory compounds (IL1-receptor antagonist, steroids, and TNF-α inhibitor) alone or in combination with a CXCR1/2 inhibitor were evaluated in their ability to improve engraftment or delay graft rejection. To rule out bias related to transplantation site, we used well-established preclinical syngeneic (250 C57BL/6 equivalent islets in C57BL/6) and allogeneic (400 Balb/c equivalent islets in C57BL6) intrahepatic islet transplantation platforms. Results. In mice, we confirmed that targeting the CXCR1/2 pathway is crucial in preserving islet function and improving engraftment. In the allogeneic setting, CXCR1/2 inhibitor alone could reduce the overall recruitment of transplant-induced leukocytes and significantly prolong the time to graft rejection both as a single agent and in combination with immunosuppression. No other anti-inflammatory compounds tested (IL1-receptor antagonist, steroids, and TNF-α inhibitor) alone or in combination with CXCR1/2 inhibitor improve islet engraftment and significantly delay graft rejection in the presence of MMF + FK-506 immunosuppressive treatment. Conclusions. These findings indicate that only the CXCR1/2-mediated axis plays a crucial role in controlling the islet damage and should be a target for intervention to improve the efficiency of islet transplantation.
R
estoration of β-cell function can be obtained by transplantation of allogeneic islets in patients with type 1 diabetes, allowing for long-term sustained function and improved metabolic control even when exogenous insulin is required (ie, suboptimal islet mass transplanted or development of graft dysfunction).
1,2 Although significant progress has been made in the islet transplantation field, 3, 4 several limitations remain that currently preclude its widespread application. Among others, the loss of as many as 50% to 75% of islets during engraftment in the liver is a main obstacle that determines the need of very large number of islets from more than 1 donor. [5] [6] [7] Moreover, the detrimental impact of inflammatory response and preexisting and transplant-induced autospecific and allospecific cellular immunoreaction are not fully addressed by the current protocols of immunosuppression. [8] [9] [10] [11] The strategy to increase immunosuppressive treatment is not practicable due to the likelihood of enhancing susceptibility to cancer and infections and to the toxicity that some of immunosuppressive drugs may have toward kidney function 12 and transplanted islets. 13 Alternatively, the development of novel protocols based on the use of more selective and specific drugs targeting inflammatory or immunosubpopulations involved in islet engraftment and/or rejection is desirable. At present, IL-1β, 14, 15 TNF-α, [16] [17] [18] leukocyte function antigen-1, 19 or the chemokine receptor for CXCL8 (CXCR1/2) 20 are the main targets of antiinflammatory strategies adapted in islet transplantation, and emerging clinical data suggest that the peritransplant inhibition of these targets could positively impact both on short-and long-term graft functions. 13 The adoption of these anti-inflammatory strategies was generally empiric 21 and driven by the availability of drugs on the market rather than by an appropriate and robust supportive mirroring validation in the preclinical phase. 14, 16 Here, using a well-established preclinical platform of intrahepatic islet transplantation, we studied comparatively the effect of TNF-α inhibitor, anti-IL1 receptor antagonist (IL1ra), CXCR1/2 inhibitor, and dexamethasone on islet engraftment and rejection. The results will be useful in choosing the best anti-inflammatory treatment in the planning of future clinical trials.
MATERIALS AND METHODS

Animals
Male C57BL/6 and Balb/c mice were purchased from Charles River Laboratories (Calco, Italy). Mice were kept under specific pathogen-free conditions and used at 8 to 9 weeks of age (24-26 g ). Diabetes (nonfasting glycemia between 450 and 600 mg/dL) 22 was induced with intravenous alloxan injection (75 mg/kg; Sigma-Aldrich, Schnelldorf, Germany) 4 days before transplantation. Blood glucose measurements were performed using a Glucometer Elite (Bayer, Toronto, Canada). All experiments were conducted in accordance with protocols approved by the Animal Care and Use Committee of San Raffaele Scientific Institute (IACUC number: 784).
Anti-Inflammatory Drugs and Immunosuppression
Reparixin, CXCR1/2 inhibitor, was provided by Dompè Farmaceutici S.p.A (L'Aquila, Italy) and administered by continuous subcutaneous infusion (Alzet osmotic pump; Alza Corporation, Palo Alto, CA) at a dose of 5.4 mg/h per kg for 7 days starting at day −1; etanercept, TNF-α inhibitor (Enbrel, Amgen Inc., Thousand Oaks, CA) active in blocking similarly both human and murine TNF-α, 23 was administered at 5 mg/kg, intraperitoneum on days −1; 0; +2; +4, and +6. Anakinra, IL1ra (Kineret, Swedish Orphan Biovitrum, Stockholm, Sweden), active in blocking similarly both human and murine IL1r, 14, 24 was administered at 100 mg/kg per day i.p. for 7 days starting at day −1; dexamethasone (Sigma-Aldrich) was administered at a dose of 1 mg/kg per day for 7 days starting at day −1; 0.9% NaCl solution was used as vehicle. Tacrolimus (FK-506, Prograf; Fujisawa Healthcare, Inc., Tokyo, Japan) was diluted in 0.9% NaCl solution and administered at 0.1 mg/kg i.p. daily starting on day −1 for 14 days; mycophenolate mofetil (MMF; CellCept, Roche Pharmaceuticals, Nutley, NJ) was administered at 60 mg/kg orally daily starting on day 0 for 14 days.
Mouse Islet Isolation and Transplantation
Pancreatic islets were isolated from C57BL/6 or Balb/c mice as previously described. 25 Islets (250 islets/ml) were cultured freely floating (37°C, 5% CO 2 ) overnight in RPMI 1640 medium supplemented with 1% L-glutamine, 1% penicillin-streptomycin and 10% fetal bovine serum (FBS, Euroclone, Milan, Italy) before transplantation. Islet purity was more than 95%, and islet mass was expressed as islet equivalent (IEQ).
Islets were transplanted via the portal vein as previously described. 25 Glycemia was measured daily for the first week and then every second day posttransplantation. In the syngeneic model, normoglycemia was defined as nonfasting glycemia less than 200 mg/dL for 2 consecutive measurements after islet transplantation. In the allogeneic model, primary nonfunction was defined as the inability to reach nonfasting glycemia under 250 mg/dL for two consecutive measurements after islet transplantation and rejection was defined as 2 successive measurements greater than 350 mg/dL in mice where primary function was achieved.
Evaluation of Intrahepatic Leukocyte Signature and After Allogeneic Islet Transplantation
For the evaluation of intrahepatic leukocyte (IHL), mice were sacrificed at days −1, 0, +1, +3, +5, +7, +10, and +14. Livers were weighed at the time of autopsy. Single-cell suspensions were prepared from 2 liver lobes of known weight, and analysis of IHL populations was performed by flow cytometry. Live/dead (Molecular Probes, ThermoFisher) staining was performed to exclude dead cells from the analysis. The cells were surface stained using the following fluorochromeconjugated monoclonal antibodies: FITC anti-CD19 (clone 1D3), PE anti-CD4 (clone RM4-5), PE-Cy7 anti-CD3 (clone 145-2C11), PB anti-CD8 (clone 53-6.7), PerCP-Cy5. + (mostly B cells). Samples were acquired on a BD FACS-Canto II instrument using FACS Diva software. Rainbow calibration particles (BD Biosciences) were used to calibrate and normalize acquisition settings in each experiment. Analysis of flow cytometry data was performed with FCS Express V4 (DeNovo Software, CA).
Statistical Analysis
Data were expressed as mean ± standard error or median and interquartile range according to their distribution. Variables with a normal distribution were compared with Student t test. Variables with an abnormal distribution were compared with Mann-Whitney U test. The time to normoglycemia achievement or to graft rejection was evaluated by the Kaplan-Meier analysis, and the significance was estimated by the log-rank test. Hazard ratios (HRs) after treatment were estimated using Cox regression. Data were analyzed using the SPSS statistical software, version 20.0 (SPSS Inc., Chicago, IL).
RESULTS
CXCR1/2 Inhibition Delays Graft Rejection and Shows an Additive Effect With Immunosuppression Treatment
We previously showed that the CXCR1/2 inhibition is able to significantly improve islet engraftment. 20 Here, we evaluated the role of this compound in preserving syngeneic β cell mass ( Figure S1 , SDC, http://links.lww.com/TP/B476) and investigated whether CXCR1/2 inhibition, alone or in combination with MMF and FK506, affects the time to rejection in an allogeneic model of islet transplantation.
Ninety-five severely diabetic C57BL/6 mice (mean nonfasting glycemia, 539 ± 64 mg/dL) were transplanted with 400 Balb/c IEQ infused in the liver and were treated with reparixin (n = 48) or vehicle (n = 47). Primary function posttransplant was achieved in 41 (85%) of 48 and 32 (68%) of 47 mice treated with reparixin or vehicle, respectively (P = 0.045). The median time to graft rejection was 10 ± 0.52 days for reparixin and 7 ± 0.3 days for vehicletreated mice (P < 0.001, Figure 1A ). Multivariate Cox regression analysis, including reparixin treatment and recipient pretransplant glycemia, 26 confirmed the CXCR1/2 inhibition treatment as a significant independent protection factor to graft loss (HR, 0.248; 95% CI, 0.114-0.541; P < 0.001) ( Figure 1B ). To characterize the IHL after intraportal islet infusion, both the phenotype and the kinetics of the recruited inflammatory cell subsets within 14 days from islet transplantation were determined by flow cytometry (Figure 2 ). Allogeneic islet infusion significantly increased all the IHL populations ( Table S1 , SDC, http://links.lww. com/TP/B476). In the presence of CXCR1/2 inhibitor treatment, a general trend to smooth the transplant induced IHL rise was evident. Concordantly, with our previously published data, 20 PMN and NKT cells recruitment was mainly inhibited by CXCR1/2 inhibition (P = 0.05) ( Table S1 , SDC, http://links.lww.com/TP/B476). CXCR1/2 inhibition was evaluated in the presence of MMF/FK-506 therapy because (i) it represents the combination of immunosuppressive drugs having limited toxicity on islet engraftment and proved efficacy in prolonging graft rejection in an intrahepatic murine model of islet transplantation 27 and (ii) it was mostly and widely used as maintenance immunosuppression regimen in the last years. Islets (400 IEQ) from Balb/c mice were transplanted in the liver of 48 severely diabetic C57BL/6 mice (mean nonfasting glycemia, 535 ± 63 mg/dL). The median survival time was 10 ± 1.58 days and 6 ± 0.7 days, respectively, for CXCR1/2 inhibitor (n = 11) and vehicletreated (n = 11) mice (P < 0.001). In the presence of MMF/ FK-506, the median survival time was 14 ± 1.4 and 9 ± 0.9 days respectively for CXCR1/2 inhibitor (n = 13) and vehicle-treated (n = 13) mice (P = 0.01) ( Figure 1C ). Multivariate Cox regression analysis, including reparixin and MMF/FK-506 treatments and recipient pretransplant glycemia, confirmed the CXCR1/2 inhibitor treatment as a significant independent protection factor for graft survival (HR, 0.094; 95% CI, 0.043-0.19; P < 0.001) ( Figure 1D ). All in all, these data demonstrate that CXCR1/2 inhibitor, both as single agent and in combination with the immunosuppressive treatment, delays graft rejection by lowering the recruitment of transplant-induced IHL populations.
TNF-a Inhibition Alone Does Not Improve Engraftment Worsening Islet Function in Combination With CXCR1/2 Inhibitor and Does Not Delay Graft Rejection
The soluble dimeric TNF-α receptor fusion protein (etanercept), an anti-inflammatory strategy already used in FIGURE 1. Pharmacologic blockade of CXCR1/2 delays graft rejection and shows an additive effect independently from immunosuppression treatment. A-B, C57BL/6 recipients were transplanted with 400 Balb/c allogeneic IEQ into the portal vein either in the presence of CXCR1/2 inhibitor (n = 48) or in the presence of vehicle (n = 47). CXCR1/2 inhibitor (5.4 mg/h per kg) or vehicle was administered by subcutaneous continuous infusion starting from day −1 to day 7 after islet transplantation. Grey area represents the anti-inflammatory treatment window. Mice that died for the surgical procedure (8/47 and 3/48 respectively for vehicle and CXCR1/2 inhibitor) were excluded from the analysis. A, Kaplan-Meier Analysis for the graft survival (<350 mg/dL). Differences between the CXCR1/2 inhibitor and vehicle were tested using the Log Rank Statistic. B, Cox regression Analysis for graft loss. C-D, C57BL/6 recipients (n = 48) were transplanted with 400 Balb/c allogeneic IEQ into the portal vein in the presence of CXCR1/2 inhibitor and/or a immunosuppressive treatment with MMF (60 mg/kg oral) + FK-506 (0.1 mg/kg, i.p.) for 14 days. Control groups were treated with vehicle. Mice that died for the surgical procedure (1/11 CXCR1/2 inhibitor; 1/11 vehicle; 1/13 MMF + FK506; 2/13 MMF + FK-506 + vehicle) were excluded from the analysis. C, Kaplan-Meier Analysis for the graft survival (<350 mg/dL). Differences were tested using the Log Rank Statistic. Grey area represents the CXCR1/2 inhibitor treatment window. D, Cox regression Analysis for graft loss.
clinical islet transplantation setting, 28 was tested in its ability to promote engraftment.
Thirty-two severely diabetic C57BL/6 recipient mice (mean nonfasting glycemia, 496 ± 81 mg/dL) were transplanted with 250 C57BL/6 syngeneic IEQ infused in the liver and treated with (i) vehicle (n = 8), (ii) etanercept (n = 8), (iii) reparixin (n = 9), or (iv) etanercept and reparixin (n = 8). Mice receiving reparixin as single agent had a significant benefit over vehicle, confirming our previous results. 20 The median time to reach normoglycemia was 1 ± 0.1 days and 11 ± 3.43 days, respectively, for CXCR1/2 inhibitor and vehicle-treated mice (P = 0.001, Figure 3A) . The use of etanercept as single agent or in combination with CXCR1/2 inhibitor failed to significantly enhance islet engraftment: in the presence of TNF-α inhibitor, the median time to reach normoglycemia was 11 ± 1.4 days and 5 ± 4.9 days, respectively, alone or in combination with CXCR1/2 inhibitor ( Figure 3A ).
Etanercept was also tested in its ability to delay rejection in the presence of MMF + FK-506. Sixty severely diabetic C57BL/6 recipient mice (mean nonfasting glycemia: 534 ± 71 mg/dL) were transplanted with 400 Balb/c allogeneic IEQ and treated with (i) MMF/FK-506/vehicle (n = 11), (ii) MMF/ FK-506/etanercept (n = 17), (iii) MMF/FK506/reparixin (n = 15), or (iv) MMF/FK506/reparixin/etanercept (n = 17). In the presence of MMF + FK-506, the median survival time was 12 ± 0.9 days and 7 ± 1.4 days, respectively, for CXCR1/ 2 inhibitor and vehicle-treated mice (P = 0.027) and 13 ± 1.8 for combination of CXCR1/2 and etanercept (P = 0.019 vs vehicle). Etanercept in the presence of MMF + FK-506 failed to prolong islet survival both alone or in association with reparixin (9 ± 2.9 days, Figure 3C ). After the correction for pretransplant glycemia, 26 multivariate Cox regression analysis confirmed the CXCR1/2 inhibitor treatment, but not the TNF-α inhibitor treatment, as a significant positive factor for reaching normoglycemia (HR, 17.37; 95% CI, 2.99-100.69; P = 0.001, Figure 3B ) and a protection factor for graft rejection (HR, 0.403; 95% CI, 0.165-0.987; P = 0.042; Figure 3D ). Altogether, these data show that TNF-α inhibitor does not improve syngeneic islet engraftment and does not prolong allogeneic graft survival neither alone nor in combination with CXCR1/2 inhibitor. Thirty-one C57BL/6 severely diabetic recipient mice (mean nonfasting glycemia, 503.7 ± 68.3 mg/dL) received, through infusion into the portal vein, 250 C57BL/6 syngeneic IEQ in the presence of dexamethasone (n = 10), reparixin (n = 6), or the combination of both treatments (n = 8). Internal control group was treated with vehicle (n = 7). The use of dexamethasone alone or in combination with CXCR1/2 inhibition failed in improving the engraftment ( Figure 4A ). After transplantation, the probability and the median time to reach normoglycemia were 71% and 17.2 ± 4.49 days in the presence of vehicle; 50% and 24 ± 2.88 days in the presence of dexamethasone; 100% and 5.1 ± 1.9 days in the presence of reparixin; 75% and 19.1 ± 3.6 days in the presence of dexamethasone and reparixin ( Figure 4A) .
In a second set of experiments, severely diabetic C57BL/6 recipient mice (n = 38, mean nonfasting glycemia: 495 ± 35 mg/dL) were transplanted with 400 Balb/c allogeneic IEQ and treated with (i) MMF/FK-506/vehicle (n = 8), (ii) MMF/FK-506/dexamethasone (n = 10), (iii) MMF/ FK-506/reparixin (n = 9), or (iv) combined treatment of dexamethasone and reparixin in the presence of MMF/FK-506 (n = 11). In the presence of MMF + FK-506, the median survival time was 12 ± 1.16 days and 3 ± 0.34 days, respectively, for CXCR1/2 inhibitor and vehicle-treated mice (P = 0.001). Dexamethasone alone or in combination with CXCR1/2 inhibitor failed to prolong islet survival once compared with the presence of immunosuppression alone as the median survival time was 5 ± 2.6 days and 8 ± 3.7 days, respectively ( Figure 4C ).
After the correction for pretransplant glycemia, 26 multivariate Cox regression analysis confirmed the CXCR1/2 inhibitor treatment, but not the dexamethasone treatment, as a significant positive factor for reaching normoglycemia (HR, 5,92; 95%; CI, 1.26-27.8; P = 0.033, Figure 4B ) and a protection factor for graft rejection (HR, 0.141; 95% CI, 0.032-0.630; P = 0.010; Figure 4D ).
Overall, dexamethasone, both alone and in combination with CXCR1/2 inhibitor, negatively impact on syngeneic islet engraftment and allogeneic graft survival.
IL1ra Negatively Impact on Syngeneic Islet Engraftment and Allogeneic Graft Survival Both Alone and in the Presence of CXCR1/2 Inhibitor
Thirty-one severely diabetic C57BL/6 recipient mice (mean nonfasting glycemia, 503 ± 40.3 mg/dL) were transplanted with 250 syngeneic C57BL/6 IEQ and treated with (i) vehicle (n = 8), (ii) IL1ra (n = 10), (iii) reparixin (n = 7), or (iv) combined treatment with IL1ra and reparixin (n = 9). The median time to reach euglycemia was 2 ± 0.8 days for vehicle-treated mice. Consistent with above results, mice receiving reparixin had a significant benefit over vehicle (1 ± 0.1 days, P = 0.025; Figure 5A ). The use of IL1ra strategy as single agent or in combination with CXCR1/2 inhibitor failed to significantly enhance islet engraftment in this model. Moreover, in the presence of IL1ra, the median time to reach normoglycemia was 8 ± 2.6 and 10 ± 1.4, respectively, alone or in combination with CXCR1/2 inhibitor.
In the allogeneic model, 42 severely diabetic C57BL/6 recipient mice (mean nonfasting glycemia, 508 ± 82 mg/dL) were transplanted with 400 allogeneic Balb/c IEQ and treated with (i) MMF/FK-506 (n = 11), (ii) MMF/FK-506/IL1ra (n = 11), (iii) MMF/FK-506/reparixin (n = 9), or (iv) combined treatment of IL1ra and reparixin in the presence of MMF/ FK-506 (n = 11). In the presence of vehicle, the median survival time was 7 ± 1.4 days. IL1ra provided a trend in delaying the time of rejection (median survival time, 10 ± 1 days; P = 0.076; Figure 5C ) but did not show any synergistic or addictive effect with reparixin.
After the correction for pretransplant glycemia, 26 multivariate Cox regression analysis confirmed the CXCR1/2 inhibitor treatment, but not the IL1ra treatment, as a significant positive factor for reaching normoglycemia (HR, 6.31; 95% CI, 1.27-31.33; P = 0.015; Figure 5B ) and a protection factor for graft rejection survival (HR, 0.273; 95% CI, 0.094-0.790; P = 0.017; Figure 5D ).
These data demonstrate that IL1ra treatment does not positively affect islet engraftment in a syngeneic transplant model and does not prolong the time to graft rejection in an allogeneic transplant model neither alone nor in the presence of CXCR1/2 inhibitor.
DISCUSSION
Growing evidences demonstrate the relevant contribution of the innate inflammatory events during islet injury posttransplantation. 20, [29] [30] [31] As previously published, immediately after transplantation, both pancreatic islets and recipient damaged hepatic tissue release high levels of inflammatory mediators like MCP-1, IL-8, IL-1, TNF-α, and interferon-γ (IFN-γ) . 20, 29, 32, 33 These chemo/cytokines are crucial in recruiting PMN and macrophages, both able to promote leukocytes infiltration 20, 34 and to amplify the expression of inflammatory mediators, including IL-1β, IL-8, IP-10, IL-6, TNF-α, and MCP-1, with deleterious effects on islet graft survival. 21, 29, 35, 36 In this direction, some studies suggested that the control of inflammatory storm could improve islet transplantation outcome 37, 38 and, according to the Clinical Islet Transplant Registry, antioxidant and antiinflammatory agents are keystone components of peritransplant management of at least 80% of transplants performed. 3 The adaption of these anti-inflammatory strategies is generally empiric 21 and driven by the availability of drugs on the market rather than by an appropriate and robust supportive mirroring validation in the preclinical phase.
14, 16 We recently demonstrated that CXCL8-CXCR1/2 axis plays a key role in promoting islet survival after transplantation 20 and in preserving β cell function in spontaneous mouse model of type 1 diabetes 39 by inhibiting leucocytes recruitment and preventing inflammation-mediated cell damage. These findings lead to the adoption of this approach in phase II (NCT01220856) and phase III (NCT01817959) multicenter clinical experiences. Here, we decided to compare and evaluate the potential synergistic effect of CXCR1/2 inhibitor with other antiinflammatory approaches. Although many anti-inflammatory compounds 40, 41 have been systemically and/or locally 42 preclinically tested with different positive impact on islet function, we selected the most relevant candidates already used in the clinical routine: TNF-α inhibitor, 43, 44 IL1ra, 45, 46 and steroids. 47 To dissect the role of these agents in improving the engraftment or delaying the rejection in intrahepatic islet transplantation, we used 2 murine experimental transplantation platforms: (i) syngeneic marginal mass model and (ii) allogeneic model in presence of partial immunosuppression MMF + FK-506. 27 Our recent publication in preclinical models showed that the use of a complete immunosuppression based on anti-CD3 T cell-depleting agent and standard immunosuppressant combination was able to significantly prolong islet survival in allogeneic context. 48 Here, we decide to use a partial immunosuppressive strategy based only on MMF plus FK-506 to open a therapeutic window able to display the impact of the different anti-inflammatory compounds alone or in combination. To rule out variability in murine islet function, we batch matched preparations for all the comparative studies.
In the marginal mass model of syngeneic intrahepatic islet transplantation, our data showed that TNF-α inhibition, steroids, and IL1ra treatment failed in significantly affecting islet engraftment. On the other hand, in all the experiments performed, the administration of CXCR1/2 inhibitor was able to significantly improve the engraftment. This confirms our previous findings where the selective inhibition of CXCR1/2-CXCL8 pathway in the intrahepatic syngeneic islet transplantation was able to dramatically reduce the infiltrating leucocytes, specifically CXCR2 + cells like PMN and NKT cells, improving transplantation outcome. 20 In agreement with our results, McCall et al 24 reported that both TNF-α inhibition and IL1ra administered alone failed to demonstrate significant benefit over control in the engraftment under the kidney capsule. Of note, the anti-TNF-α blockade was integrated into clinical islet transplantation largely based on a single publication 21 and supported by a single-donor islet transplant series in which etanercept was included as drug both in islet culture preparation and during peritransplant management. 28 Even if adapted as standard therapy by some groups, 49 ,50 2 randomized controlled studies 24 ,51 failed to demonstrate a significant clinical benefit of anti-TNF-α blockade. Similarly, IL1ra was integrated in the clinical islet transplantation application in combination with TNF-α inhibition strategy. Preclinical results showed a role of this combinatory therapy in a syngeneic marginal mass model under the kidney capsule without additional data in the allogeneic model or in the intrahepatic setting. 24 In allogeneic model in presence of standard partial immunosuppression, MMF + FK-506 results showed that the combination of TNF-α inhibition, steroids administration, and IL1-ra treatment with an effective immunosuppressive regimen failed to significantly prolong islet survival and confirmed that only the adoption of CXCR1/2 inhibitor was able to delay graft rejection. In addition, the combination of CXCR1/2 inhibitor with the other anti-inflammatory compounds did not significantly improve the time of rejection compared with the use of CXCR1/2 inhibitor alone. Moreover, also in the allogeneic setting without MMF + FK-506 treatment, CXCR1/2 inhibitor was able to reduce the overall infiltrated leukocytes and significantly prolong the time to rejection. Altogether, these evidences strongly suggest that even if inflammatory injury of transplanted islets is a major target, not all the inflammatory mediators are equally relevant, and a major effort should be directed to the identification of the key regulators of this process. Of note, the inhibition of peritransplant inflammatory reaction mediated by CXCR1/ 2 axis positively impacts on islet transplantation outcome; on the other hand, the simultaneous shutdown of several inflammatory mediators negatively affected both islet engraftment and survival. In this direction, it is well known that inflammation is a key point in the tissue remodelling. Angiogenesis and inflammation are linked and represent pivotal processes to achieve graft function. Several publications have FIGURE 5 . Comparison of outcomes after syngeneic and allogeneic islet transplantation in the presence of CXCR1/2 inhibitor and/or IL1ra. A-B, C57BL/6 recipients (n = 31) were transplanted with 250 syngeneic IEQ into the portal vein in the presence of CXCR1/2 inhibitor (n = 7; s.c. continuous infusion for 7 days starting from day −1 at a dose of 5.4 mg/kg/h) and/or IL1ra (n = 10; 100 mg/kg per day i.p. for 7 days starting at day −1). Control groups of mice were treated with vehicle (n = 8). Mice that died for the surgical procedure (2/8 vehicle, 3/10 IL1ra, and 2/7 CXCR1/2 inhibitor groups) were excluded from the analysis. A, Kaplan-Meier analysis for the gain of normoglycemia (<200 mg/dL). Differences were tested using the log rank statistic. Grey area represents the anti-inflammatory treatment window. B, Cox regression analysis for the gain of normoglycemia. C-D, C57BL/6 recipients (n = 40) were transplanted with 400 Balb/c allogeneic IEQ into the portal vein in the presence of immunosuppressive treatment with MMF (60 mg/kg, oral) + FK-506 (0.1 mg/kg, i.p.) for 14 days. CXCR1/2 inhibitor and/or IL1ra were added with the same doses and schedules used for syngeneic model. Control groups of mice were treated with vehicle. Mice that died for the surgical procedure (2/11 MMF/FK-506/vehicle, 1/11 MMF/FK-506/ILra, and 1/11 MMF/FK-506/CXCR1/2/IL1ra). Normoglycemia within 5 days was reached in 100% in reparixin (9 of 9) and IL1ra (10 of 10) groups, 87.5% (7 of 8) in vehicle group and 88.8% (8 of 9) in the combination of reparixin + IL1ra. C, Kaplan-Meier analysis for the graft survival (<350 mg/dL). Differences were tested using the log rank statistic. D, Cox regression analysis for graft loss.
already showed that the selective inhibition of IL1 and/or TNF-α could potentially inhibit angiogenesis, [52] [53] [54] suggesting that the negative combinatorial effect of these compounds on islet engraftment could be due to a delayed and/or impaired revascularization. As well in the intrahepatic islet transplantation, it is mandatory the identification of selected inflammatory pathways able to reduce the transplant-driven inflammation and improve hepatic tissue remodelling.
In summary, the current study provides important supportive data that confirmed the relevant role of the CXCR1/2 inhibition as a relevant candidate in playing a crucial role in controlling islet inflammatory mediated damage. The overall comparison with the other relevant anti-inflammatory agents showed that targeting exclusively CXCR1/2 pathway is able not only to improve the islet engraftment in the hepatic site but also to delay the time of rejection.
